Temodar® (temozolomide) is a chemotherapy medicine used to treat glioblastoma multiforme and anaplastic astrocytoma, which are types of brain tumors. But how effective is Temodar at treating these tumors?
Clinical studies have shown that Temodar improved survival in people who had these types of brain tumors. In the studies of people with glioblastoma multiforme, people who received Temodar and radiation therapy lived about 2.5 months longer than those treated with just radiation therapy.
In studies on people who had anaplastic astrocytoma that had worsened despite other treatment, about 22 percent of people were said to respond to treatment with Temodar. These studies showed that approximately 65 percent of those treated were still alive after 12 months of treatment.
(For more details on the effectiveness of this drug, click Temodar. This full-length article covers a number of topics, including how this drug works, potential side effects, and why it is not appropriate for some people.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed August 2, 2012.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2008.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click